Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size (2024 - 2029)

The veterinary active pharmaceutical ingredients manufacturing market is projected to experience significant growth over the forecast period, driven by factors such as the increasing prevalence of zoonotic diseases and the rising pet population. The market's expansion is further supported by the growing demand for effective treatment options due to the heightened risk of viral spread among domesticated animals, as observed during the COVID-19 pandemic. Despite challenges like rising costs and stringent regulations, the market is expected to benefit from strategic initiatives by key players, including product launches and mergers, which aim to enhance their market position.

Market Size of Veterinary Active Pharmaceutical Ingredients Manufacturing Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Veterinary Active Pharmaceutical Ingredients Manufacturing Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 7.24 Billion
Market Size (2029) USD 10.21 Billion
CAGR (2024 - 2029) 7.10 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Veterinary Active Pharmaceutical Ingredients (API) Market Analysis

The Veterinary Active Pharmaceutical Ingredients Manufacturing Market size is estimated at USD 7.24 billion in 2024, and is expected to reach USD 10.21 billion by 2029, growing at a CAGR of 7.10% during the forecast period (2024-2029).

The COVID-19 epidemic has had a significant impact on the market. Several animals, including cats, gorillas, dogs, farmed mink, otters, and others, were infected with the virus, which resulted in an increased risk of viral spread among domesticated animals, in turn boosting the demand for veterinary drugs. However, amid the pandemic, the prices of some veterinary APIs and feed additives rose sharply. According to a publication by Hangzhou DE Mark Industrial Co. Ltd., a manufacturer of veterinary pharmaceutical raw materials and specialty feed additives, in January 2022, the price of vitamin C grew dramatically, reaching roughly 30 RMB (USD 4.19) per kg, an almost 50% increase. While the cost of Vitamin D3 nearly doubled. Thus, such an increase associated with the prices of veterinary manufacturing products adversely impacted the market's growth during the pandemic. However, increasing incidences of COVID-19 among animals have surged the demand for several drugs to combat the SARS-CoV-2 virus, which is anticipated to have a positive impact on the market's growth. For instance, as per CDC and NCEZID data published in March 2022, more than 200 pets, including dogs, ferrets, and cats, were infected by the SARS-CoV-2 virus in the United States. Therefore, as per the analysis, such incidences are projected to augment market growth over the coming years.

The factors expected to drive the market growth include the increasing prevalence of zoonotic diseases, increasing animal populations and pet ownership, and rising numbers of veterinarians and veterinary visits. The market is highly propelled by the elevated prevalence of zoonotic diseases. Since human-animal connections are necessary for existence, this makes zoonoses easier to spread. Human-animal cohabitation is more common in poorer nations, particularly among rural populations. This inextricable relationship is evidenced by the higher occurrence of zoonoses in underdeveloped countries.

For instance, the Indian Journal of Medical Research in 2021 stated that animals are responsible for 70% of emerging infectious diseases; every year, five new diseases are generated, three of which are of animal origin, and zoonotic infections account for 80% of agents with potential bioterrorism use. In May 2022, the USDA Animal and Plant Health Inspection Service (APHIS) and the New Jersey Department of Agriculture (NJDA) confirmed New Jersey's first highly pathogenic avian influenza case in a Monmouth County non-commercial backyard poultry flock. As a result of the increasing prevalence of infectious diseases, there is a greater need for effective treatment options, which increases the demand for active pharmaceutical ingredient manufacturing and supports market growth.

Moreover, the increasing pet population and pet adoption are expected to propel the market's growth. For instance, according to the People's Dispensary for Sick Animals (PDSA) PAW Report 2021, there were 9.6 million pet dogs, 10.7 million pet cats, and 900,000 pet rabbits in the United Kingdom. The same source also reported 2 million pets being adopted since March 2020 in the United Kingdom. The pet population is susceptible to several diseases, and thus, increased adoption of this population is expected to raise demand for veterinary drugs, ultimately boosting the market's growth.

Various strategies adopted by the key market players, such as product launches, mergers, and acquisitions, are expected to boost the market over the forecast period. For instance, in November 2021, ArchiMed acquired the majority of its stake in Madrid-based SuanPharma, a provider of veterinary active pharmaceutical ingredients. The goal was to finance ambitious industrial consolidation and organic expansion to position it as a leader in the API industry.

Thus, all the above-mentioned factors, such as the growing prevalence of zoonotic diseases and the rising adoption of animals, are expected to boost market growth over the forecast period. However, lack of awareness and the high cost of animal care coupled with stringent regulations may restrain the market over the forecast period.

Veterinary Active Pharmaceutical Ingredients (API) Industry Segmentation

As per the scope of this report, the biologically active component of a medicine used to treat animals as a tablet, pill, cream, or injection that causes the desired effects is known as the Veterinary Active Pharmaceutical Ingredient (API). The component of medicine that generates the desired effects is known as the active pharmaceutical ingredient (API). Combination therapies have various active substances that cure distinct symptoms or work in different ways. The Veterinary Active Pharmaceutical Ingredients Manufacturing Market is segmented by Product (Antiparasitic, Anti-infectives, Vaccines, NSAIDs, Others), Synthesis Type (Chemical Based API, Biological API, Highly potent API (HPAPI)), Service Type (In House, Contract Outsourcing (Contract Development, Contract Manufacturing), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product
Antiparasitic
Anti-infectives
Vaccines
NSAIDs
Others
By Synthesis Type
Chemical Based API
Biological API
Highly Potent API (HPAPI)
By Service Type
In House
Contract Outsourcing
Contract Development
Contract Manufacturing
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size Summary

The veterinary active pharmaceutical ingredients manufacturing market is poised for significant growth, driven by factors such as the increasing prevalence of zoonotic diseases, rising pet ownership, and the growing number of veterinarians and veterinary visits. The market has been impacted by the COVID-19 pandemic, which heightened the demand for veterinary drugs due to infections in various animal species. Despite challenges like price surges in certain veterinary APIs and feed additives during the pandemic, the demand for drugs to combat animal infections has positively influenced market expansion. The market is also supported by strategic initiatives from key players, including mergers, acquisitions, and product launches, which aim to enhance their market position and drive growth.

The market's growth is further bolstered by the rising need for vaccines, driven by the high frequency of chronic diseases in animals and the increasing livestock populations. The establishment of new vaccine manufacturing facilities and the development of technologically advanced vaccines are expected to meet the growing demand. North America is anticipated to hold a significant market share, supported by a high pet ownership rate and increased expenditure on veterinary care. The region's market growth is also fueled by rising R&D investments and advancements in veterinary procedures. The competitive landscape is dominated by major players such as Zoetis, SUANFARMA, and Alivira Animal Health Limited, who are actively expanding their portfolios and capabilities to capture a larger market share.

Explore More

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence of Zoonotic Diseases

      2. 1.2.2 Increasing Animal Population And Pet Ownership

      3. 1.2.3 Rising Number of Veterinarians and Veterinary Visits

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Awareness and High Cost of Animal Care

      2. 1.3.2 Stringent Government Regulations

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Product

      1. 2.1.1 Antiparasitic

      2. 2.1.2 Anti-infectives

      3. 2.1.3 Vaccines

      4. 2.1.4 NSAIDs

      5. 2.1.5 Others

    2. 2.2 By Synthesis Type

      1. 2.2.1 Chemical Based API

      2. 2.2.2 Biological API

      3. 2.2.3 Highly Potent API (HPAPI)

    3. 2.3 By Service Type

      1. 2.3.1 In House

      2. 2.3.2 Contract Outsourcing

        1. 2.3.2.1 Contract Development

        2. 2.3.2.2 Contract Manufacturing

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle-East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size FAQs

The Veterinary Active Pharmaceutical Ingredients Manufacturing Market size is expected to reach USD 7.24 billion in 2024 and grow at a CAGR of 7.10% to reach USD 10.21 billion by 2029.

In 2024, the Veterinary Active Pharmaceutical Ingredients Manufacturing Market size is expected to reach USD 7.24 billion.

Veterinary API Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)